Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy
- PMID: 34048675
- DOI: 10.1016/S2352-3026(21)00140-X
Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy
Conflict of interest statement
SB has received research funding from Amyloid Foundation. LJC received honoraria and grant or research support from Amgen, Bristol-Myers Squibb, AbbVie, and Janssen.
Comment on
-
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.Lancet Haematol. 2021 Jun;8(6):e422-e432. doi: 10.1016/S2352-3026(21)00130-7. Lancet Haematol. 2021. PMID: 34048681 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
